Home » Generic Injectables Market Trends, Share, Size, Outlook 2022-2027

Generic Injectables Market Trends, Share, Size, Outlook 2022-2027

by Maria James
Generic Injectables Market

Global Generic Injectables Market Overview:

The latest report published by IMARC Group, titled “Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the generic injectables market outlook. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global generic injectables market reached a value of US$ 40.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 65.4 Billion by 2027, exhibiting at a CAGR of 8.6% during 2022-2027.

Generic injectables are alternative drugs that are bio-equivalent to their branded counterparts. They contain similar active ingredients, strength, quality, effectiveness, intended use, and dosage. These injectables help in the easy absorption of drugs into the body in liquid form, which reduces the frequency of dosage administration without affecting the effectiveness of the treatment. They are also cost-effective as they do not require investments in research and development (R&D) and promotional activities.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Generic Injectables Market Trends:

Nowadays, the governing authorities of numerous countries are undertaking favorable initiatives to support the manufacturing of generic injectables. This can be accredited to the rising drug shortage and upcoming patent expiry of several branded drugs. Besides this, the increasing prevalence of chronic diseases like diabetes, cardiovascular disorders, and Alzheimer’s and the rising geriatric population that is more susceptible to such ailments are positively influencing the market growth.

Moreover, generic injectables are widely adopted by patients who are unable to take medicines by mouth and have poor intestinal absorption. In addition, various key players are engaging in mergers and acquisitions (M&As) and partnerships to develop complex and differentiated products, which is creating a favorable market outlook across the globe.

Furthermore, the emergence of self-injection devices, the improving healthcare infrastructures in developed and developing economies, and rapid technological advancements in drug delivery systems are some of the other factors augmenting the market growth.

Global Generic Injectables Market 202-2027 Analysis and Segmentation

Competitive Landscape with Key Players:

Hospira, Inc. (Pfizer Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sandoz (Novartis), Sagent M&C, LLC, Sanofi S.A., and Baxter International, Inc.

Also, Read the Full Blog: List of the Top Generic Pharmaceuticals Injectables Companies Worldwide

Breakup by Therapeutic Area:

On the basis of the therapeutic area, the market has been classified into oncology, anesthesia, anti-infectives, parental nutrition and cardiovascular.

Amongst these, the oncology segment holds the largest market share.

Breakup by Container:

Based on the container, the market has been categorized into vials, ampoules, premix, and prefilled syringes.

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacy

Breakup by Region:

Region-wise, North America holds the leading position in the market. Other major regions include Europe, Asia, Middle East and Africa, and Latin America.

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

TOC for the Generic Injectables Market Research Report:

  • Preface
  • Scope and Methodology
  • Executive Summary
  • Introduction
  • Generic Injectables Market SWOT Analysis
  • Value Chain Analysis
  • Price Analysis
  • Competitive Landscape

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Therapeutic Area, Container, Distribution Channel, Region
Region Covered  Asia, Europe, North America, Latin America, Middle East and Africa
Companies Covered Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Read More: https://foodtravellibrary.com/

You may also like

Leave a Comment